Literature DB >> 18521267

Susceptibility of fibromatosis cells in short-term culture to Ifosfamide: a possible experimental treatment in clinically aggressive cases.

M W Verrill1, H M Coley, I R Judson, C Fisher.   

Abstract

Purpose. Deep fibromatoses are large, often rapidly growing but benign soft tissue tumours. Although surgery is the mainstay of treatment, in unremitting and aggressive cases the use of cytotoxic chemotherapy may produce objective tumour responses. Fresh tumour samples from four patients with fibromatosis were investigated as part of a study of drug resistance in soft tissue tumours.Methods. Following short-term culture of fibromatosis cells in vitro , chemosensitivity to 4-hydroperoxy-ifosfamide, the active form of ifosfamide and doxorubicin was tested. Following 72-h continuous exposure to each drug, surviving cell fraction was assessed using the lactate dehydrogenase assay.Results. Mean IC(50) values for ifosfamide and doxorubicin were 6.2 and 0.35 micromol/l, respectively. In samples of soft tissue sarcoma (STS) from the same study the mean IC(50) values for ifosfamide and doxorubicin were 14.8 and 1.69 micromol. The difference in mean ifosfamide IC(50) values for fibromatosis and STS samples was statistically significant.Discussion. We are not aware of any other report suggesting the use of ifosfamide in this condition. These observations suggest that, for patients with inoperable or progressive lesions of fibromatosis causing significant morbidity, it may be valuable to include ifosfamide in experimental treatment regimens.

Entities:  

Year:  1999        PMID: 18521267      PMCID: PMC2395416          DOI: 10.1080/13577149977686

Source DB:  PubMed          Journal:  Sarcoma        ISSN: 1357-714X


  23 in total

1.  Radiation therapy for aggressive fibromatosis. The Experience at the University of Florida.

Authors:  W M McCollough; J T Parsons; R van der Griend; W F Enneking; T Heare
Journal:  J Bone Joint Surg Am       Date:  1991-06       Impact factor: 5.284

2.  Chemosensitivity testing of fresh and continuous tumor cell cultures using lactate dehydrogenase.

Authors:  H M Coley; G Lewandowicz; J M Sargent; M W Verrill
Journal:  Anticancer Res       Date:  1997 Jan-Feb       Impact factor: 2.480

3.  The desmoid tumor. Not a benign disease.

Authors:  M C Posner; M H Shiu; J L Newsome; S I Hajdu; J J Gaynor; M F Brennan
Journal:  Arch Surg       Date:  1989-02

4.  Recent trends in the management of desmoid tumors. Summary of 19 cases and review of the literature.

Authors:  D W Easter; N A Halasz
Journal:  Ann Surg       Date:  1989-12       Impact factor: 12.969

5.  Nonsurgical management of children with recurrent or unresectable fibromatosis.

Authors:  B Raney; A Evans; L Granowetter; L Schnaufer; A Uri; P Littman
Journal:  Pediatrics       Date:  1987-03       Impact factor: 7.124

6.  Management of desmoid tumors.

Authors:  J G McKinnon; J P Neifeld; S Kay; G A Parker; W C Foster; W Lawrence
Journal:  Surg Gynecol Obstet       Date:  1989-08

7.  Desmoid tumors of the chest wall. A locally recurrent problem.

Authors:  J T Brodsky; M S Gordon; S I Hajdu; M Burt
Journal:  J Thorac Cardiovasc Surg       Date:  1992-10       Impact factor: 5.209

8.  Low-dose chemotherapy of desmoid tumors.

Authors:  A J Weiss; R D Lackman
Journal:  Cancer       Date:  1989-09-15       Impact factor: 6.860

9.  Extra-abdominal desmoid tumors.

Authors:  G Markhede; L Lundgren; N Bjurstam; O Berlin; B Stener
Journal:  Acta Orthop Scand       Date:  1986-02

Review 10.  Endocrine therapy for desmoid tumors.

Authors:  N Wilcken; M H Tattersall
Journal:  Cancer       Date:  1991-09-15       Impact factor: 6.860

View more
  1 in total

1.  Desmoid tumor treated with polychemotherapy followed by imatinib: a case report and review of the literature.

Authors:  Gudrun Knechtel; Herbert Stoeger; Joanna Szkandera; Katrin Dorr; Alfred Beham; Hellmut Samonigg
Journal:  Case Rep Oncol       Date:  2010-08-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.